PharmAust Gets approval to increase dosage in MPL trial
- PharmAust (PAA) has received the green light from the trial safety committee to increase the tablet dosage in its motor neurone disease study
- The company reported no safety issues or serious adverse events found during its study, as a result of the treatment
- The company says it will continue supplying MPL tablets to all six patients in cohort one, with a four-week escalating dose of the MPL tablets set to begin
- Patient recruitment for the next stage MPL dosing level has started, with four new patients currently undergoing screening
- The company shares were up 1.15 per cent, trading at 8.8 cents at 1:15 pm AEDT
